PubMed ID:
21791356
Public Release Type:
Journal
Publication Year: 2011
Affiliation: Section of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA.
DOI:
https://doi.org/10.1016/j.juro.2011.04.062
Authors:
Bruskewitz R,
Crawford ED,
Donnell RF,
Hirst K,
Kaplan SA,
Kusek JW,
McVary KT,
Mynderse LA,
Roehrborn CG,
Smith CP
We conducted a 2-stage, multicenter, double-blind, randomized phase II clinical trial of 100 and 300 unit doses of onabotulinum toxin A to treat the lower urinary tract symptoms of benign prostatic hyperplasia.